secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076575
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health Q4 revenue $148.5M, net loss $31.3M; Regeneron deal >$1B
--------------------------------------------------------------------

- Q4 revenue $148.5M (down 19% YoY); net loss $31.3M ($0.04/share) vs $14.0M income in Q4 2024.
- Regeneron collaboration for multispecific antibodies: upfront + milestones >$200M per program, total >$1B.
- Pharmaceuticals revenue $43.7M (+17% YoY); NGENLA profit share $12.5M, Rayaldee $8.8M.
- Diagnostics revenue $71.1M (down 31% YoY) on asset sale; operating loss improved to $18.3M from $21.7M.
- FY 2026 guidance: total revenue $530-560M; total costs $725-750M; R&D $125-135M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000119312526076575/0001193125-26-076575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000119312526076575/opk-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer